Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
68 hedge funds and large institutions have $160M invested in Concert Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
55% more capital invested
Capital invested by funds: $103M → $160M (+$56.5M)
26% more funds holding
Funds holding: 54 → 68 (+14)
6.17% more ownership
Funds ownership: 42.51% → 48.68% (+6.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.21M |
| 2 |
Jennison Associates
New York
|
+$6.7M |
| 3 |
SAM
Senzar Asset Management
New York
|
+$3.49M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.14M |
| 5 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.52M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.52M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.24M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$559K |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
-$283K |
CNCE Hedge Fund Activity: Q1 2015 in Review
68 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2015, worth a combined $160M — up 55% from $103M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CNCE positions and 6 closed out — a net gain of 14 holders — while 24 added to existing stakes and 14 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $9.21M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $1.52M sold.
- 68 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2015, up from 54 in Q4 2014.
- Funds reported $160M of Concert Pharmaceuticals, Inc. stock for Q1 2015, up 55% quarter-over-quarter.
- 20 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2015 and 6 closed out, a net change of +14 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2015 was RA Capital Management, an estimated $9.21M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2015 was Bogle Investment Management, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2015.